GastroEsophageal Cancer

New Reference: DOCEtaxel, OXALIplatin, Capecitabine in Locally Advanced Gastric Cancer

2023-11-20

  • Study

    Randomized, open-label, phase 3 trial
    Potentially resectable, locally advanced cT3-4 gastric adenocarcinoma in patients younger than 60 years
    Neoadjuvant Docetaxel, Oxaliplatin, Capecitabine (n = 93) vs Neoadjuvant Oxaliplatin, Capecitabine (n = 92) vs Surgery alone (n = 95)


  • Efficacy

    Pathological CR: 16.1% vs 4.3%, p = 0.008
    3-yr OS: 56.9% vs 44.6% (HR 0.64 [0.42 – 0.97], p = 0.037) vs 34.7%
    3-yr DFS: 45.2% vs 40.2% (HR 0.75 [0.50 – 1.10], p = 0.091) vs 28.4%


  • Safety

    N/A


    • Int J Surg 2023 Sep 4

    Neoadjuvant docetaxel, oxaliplatin plus capecitabine versus oxaliplatin plus capecitabine phase III randomized controlled clinical trial for patients with locally advanced gastric adenocarcinoma: long-term results of a randomised controlled trial

    http://doi.org/10.1097/JS9.0000000000000692

    Reviewed by Elvin Chalabiyev, MD on Nov 20, 2023